Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

NCT04983407 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

INDUSTRY

Sponsor class

Stopped Due to business reasons

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: batiraxcept
DRUG: Nab paclitaxel
DRUG: Gemcitabine

Sponsor

Aravive, Inc.